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Abstract. 
 
Type II procollagen is expressed as two splice 
forms. One form, type IIB, is synthesized by chondro-
cytes and is the major extracellular matrix component 
of cartilage. The other form, type IIA, contains an addi-
tional 69 amino acid cysteine-rich domain in the NH
 
2
 
-
propeptide and is synthesized by chondrogenic mesen-
chyme and perichondrium. We have hypothesized that 
the additional protein domain of type IIA procollagen 
plays a role in chondrogenesis. The present study was 
designed to determine the localization of the type IIA 
NH
 
2
 
-propeptide and its function during chondrogene-
sis. Immunoﬂuorescence histochemistry using antibod-
ies to three domains of the type IIA procollagen mole-
cule was used to localize the NH
 
2
 
-propeptide, ﬁbrillar 
domain, and COOH-propeptides of the type IIA pro-
collagen molecule during chondrogenesis in a develop-
ing human long bone (stage XXI). Before chondro-
genesis, type IIA procollagen was synthesized by 
chondroprogenitor cells and deposited in the extracel-
lular matrix. Immunoelectron microscopy revealed 
type IIA procollagen ﬁbrils labeled with antibodies to 
 
NH
 
2
 
-propeptide at 
 
z
 
70 nm interval suggesting that the 
NH
 
2
 
-propeptide remains attached to the collagen mole-
cule in the extracellular matrix. As differentiation pro-
ceeds, the cells switch synthesis from type IIA to IIB 
procollagen, and the newly synthesized type IIB col-
lagen displaces the type IIA procollagen into the inter-
territorial matrix. To initiate studies on the function of 
type IIA procollagen, binding was tested between re-
combinant NH
 
2
 
-propeptide and various growth factors 
known to be involved in chondrogenesis. A solid phase 
binding assay showed no reaction with bFGF or IGF-1, 
however, binding was observed with TGF-
 
b
 
1 and
BMP-2, both known to induce endochondral bone for-
mation. BMP-2, but not IGF-1, coimmunoprecipitated 
with type IIA NH
 
2
 
-propeptide. Recombinant type IIA 
NH
 
2
 
-propeptide and type IIA procollagen from media 
coimmunoprecipitated with BMP-2 while recombinant 
type IIB NH
 
2
 
-propeptide and all other forms of type II 
procollagens and mature collagen did not react with 
BMP-2. Taken together, these results suggest that the 
NH
 
2
 
-propeptide of type IIA procollagen could function 
in the extracellular matrix distribution of bone morpho-
genetic proteins in chondrogenic tissue.
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2
 
-
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L
 
ONG
 
 bones and many other components of the skeleton
are formed through endochondral ossification, a
process wherein bone is laid down on cartilaginous
anlagen. The ultimate pattern of these bones is deter-
mined by the location and extent of cartilage formation,
i.e., during chondrogenesis. In 1986, Thorogood and col-
leagues first suggested that type II collagen, the character-
istic structural collagen of cartilage, plays a role in induc-
tion of chondrogenesis (Thorogood et al., 1986; Wood et al.,
1991). Epithelial cell–derived type II collagen or associ-
ated components of the extracellular matrix (ECM)
 
1
 
 were
proposed to provide a template that mediates the differen-
tiation and patterning of the cartilaginous neurocranium
by chondrogenic mesenchyme. Evidence for this hypothe-
sis came from a number of sources including the presence
of immunodetectable type II collagen in neuroepithelial
and chondrogenic tissues at sites of future chondrogenesis
in chicken (Thorogood et al., 1986), mouse (Wood et al.,
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1991), 
 
Xenopus
 
 (Seufert et al., 1994), and zebrafish (Yan
et al., 1995). Type II collagen was also detected at epithe-
lial–mesenchymal boundaries at various sites in the body
trunk (Kosher and Solursh, 1989) and accumulates in the
cell-free region adjacent to the embryonic notochord, into
which somatic sclerotomal cells expand before differentia-
tion into vertebral cartilage (von der Mark et al., 1976).
mRNA encoding type II collagen is temporally expressed
by both epithelial and mesenchymal induction partners
(Cheah et al., 1991), notochord (Sandell, 1994), and in
chondrogenic mesenchyme (Kosher et al., 1986).
We now know that type II collagen is synthesized in two
splice forms, type IIA and IIB. Type IIA is synthesized by
precartilage and noncartilaginous epithelial and mesen-
chymal cells (Sandell et al., 1991, 1994; Ng et al., 1993)
while type IIB collagen is synthesized by chondrocytes.
Type IIA procollagen is an mRNA splice form that con-
tains an additional 207 base pair exon (exon 2) encoding
the 69 amino acid cysteine-rich domain of the NH
 
2
 
-pro-
peptide (Ryan and Sandell, 1990; Sandell et al., 1994).
From studies examining the mRNA expression pattern of
type IIA procollagen (Nah and Upholt, 1991; Ng et al.,
1993; Sandell et al., 1994; Nalin et al., 1995), we hypothe-
sized that this additional protein domain may play a role in
chondrogenesis. We and others have shown that type IIA
procollagen mRNA precedes type IIB procollagen mRNA
expression during formation of the endochondral skele-
ton. For example, type IIA procollagen mRNA is present
in the somites, notochord, neuroepithelia, and prechon-
drogenic mesenchyme of mouse (Ng et al., 1993; Sandell
et al., 1994) and human (Sandell et al., 1991; Lui et al.,
1995) embryos, and in precartilaginous condensations and
perichondrium during development of avian long bones
(Nalin et al., 1995). In tissues that undergo chondrogene-
sis, the mRNA splice form switches from type IIA to IIB
procollagen upon differentiation into chondroblasts. In
nonchondrogenic tissue, the synthesis of type IIA procol-
lagen is transient. Recent studies using an antibody spe-
cific to type IIA procollagen NH
 
2
 
-propeptide have es-
tablished its presence in human prechondrogenic, early
cartilage, and epithelial tissues (Oganesian et al., 1997).
Fibrillar collagens such as type II are initially translated
as procollagens that include both an NH
 
2
 
- and a COOH-
terminal propeptide. An NH
 
2
 
-propeptide similar to the
type IIA NH
 
2
 
-propeptide is found in the other fibrillar col-
lagens, types I, III, and V. From studies in tissue culture
and the isolation of collagens from adult tissues, it has
been shown that both propeptides are removed before se-
cretion, and only the triple-helical collagen is deposited
into the ECM. In contrast, in embryonic tissues, type I and
III procollagens retaining the NH
 
2
 
-propeptide have been
identified (Fleischmajer et al., 1990). It has been suggested
that propeptides play a role in the regulation of fibril di-
ameter (Fleischmajer et al., 1990), and feedback regula-
tion of collagen synthesis (Weistner et al., 1979; Horlein
et al., 1981; Wu et al., 1986; Fouser et al., 1991); however,
no definitive function has been proven.
Recently, two new proteins have been identified that
contain multiple copies of a domain homologous to col-
lagen NH
 
2
 
-propeptides, sog (short gastrulation gene) in
 
Drosophila
 
 (Francois and Bier, 1995), and chordin in 
 
Xe-
nopus
 
 (Sasai et al., 1994). Elegant studies have shown that
 
sog and chordin function to establish a dorsal–ventral pat-
tern by binding to members of the TGF-b superfamily
(decapentaplegic and BMP-4, respectively) to establish a
gradient of available morphogen (Francois et al., 1994;
Sasai et al., 1994, 1995; Piccolo et al., 1996). The bone mor-
phogenetic proteins (BMPs) are members of the TGF-
 
b
 
superfamily and were originally identified because of their
ability to induce cartilage and bone formation (Reddi,
1995; Hogan, 1996).
The present study was designed to explore the function
of type IIA NH
 
2
 
-propeptide in chondrogenesis. The hy-
pothesis tested was that type IIA NH
 
2
 
-propeptide is pres-
ent in the ECM and can function to bind growth factors or
cytokines. Of particular interest was whether type IIA
NH
 
2
 
-propeptide could bind to members of the TGF-
 
b
 
 su-
perfamily in order to regulate the availability of the mor-
phogen in prechondrogenic mesenchyme in a manner sim-
ilar to the function of sog and chordin in dorsal–ventral
patterning. If so, a direct mechanistic connection would be
established between the patterning of the body axis and
the patterning of the skeleton. We show that during chon-
drogenesis in the limb, type IIA is synthesized as a procol-
lagen retaining the cysteine-rich amino propeptide, and
it is incorporated into fibrils and deposited into the ECM
of precartilaginous mesenchyme. Furthermore, the NH
 
2
 
-
propeptide binds to members of the TGF-
 
b
 
 superfamily,
namely TGF-
 
b
 
1 and BMP-2. We propose that this inter-
action could potentially localize the factors capable of in-
ducing chondrogenesis. These findings suggest a novel
function for the collagen NH
 
2
 
-propeptide and begin to es-
tablish a mechanistic paradigm for the regulation of pat-
tern formation in basic body plan and the skeleton.
 
Materials and Methods
 
Tissues 
 
Tissues used in this study were stage XXI human fetal limbs, 50-d gesta-
tion, provided by the Central Laboratory for Human Embryology (Uni-
versity of Washington, Seattle, WA). Tissues were frozen in OCT com-
pound (Miles Laboratories Inc.) and sectioned with cryostat. The sections
(8–10 
 
m
 
m) were stored at 
 
2
 
70
 
8
 
C until used.
 
In Situ Hybridization
 
 
 
Probes specific for type IIA and IIB procollagen were used. A 207-bp
cDNA, H-IIA, encoding exon 2 of human collagen type II
 
a
 
1(II) was used
to detect type IIA procollagen mRNA. Primers (5
 
9
 
 primer, 5
 
9
 
-CGT-
GAATTCCAGGAGGCTGGCAGCTGTGTG-3
 
9
 
; 3
 
9
 
 primer, 5
 
9
 
-GAT-
GGATCCGGCGAGGTCAGTTGGGCAGAT-3
 
9
 
) that flank the exon 2
splice site were used to amplify a 207-bp fragment with EcoRI and BamHI
restriction sites from 54-d human fetal embryonic tissue total RNA by us-
ing reverse transcription-polymerase chain reaction (RT-PCR), and
cloned into pGEM-3zf(
 
1
 
) expression vector (Promega Corp.). This con-
struct was used to generate antisense and sense riboprobes by in vitro
transcription for
 
 
 
in situ hybridization. Antisense 
 
35
 
S-labeled RNA probe
was transcribed by SP6 RNA polymerase on EcoRI linearized DNA tem-
plate. Sense RNA probe was transcribed by T7 RNA polymerase on
DNA template linearized with BamHI. The RNA transcripts were labeled
with a 
 
35
 
S-UTP (New England Nuclear). For detecting human type IIB
procollagen mRNA, an oligonucleotide probe was used containing 12 nu-
cleotides of exons 1 and 12 nucleotides of exon 3, 5
 
9
 
-CTCCTGGTTGC-
CGGACATCCTGGC-3
 
9
 
 (Ryan and Sandell, 1990). The probe was la-
beled with 5
 
9
 
-(a-thiol-
 
35
 
S)-ATP (New England Nuclear) using terminal
deoxynucleotidyl transferase. In situ hybridization was performed as de-
scribed previously (Sandell et al., 1991; Wilcox, 1993). 
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Antibodies 
 
Three antibodies were used for immunohistochemistry of type II procol-
lagen, and another two were used to detect BMP-2 and IGF-1 by ELISA
and Western blots. Rabbit antisera against recombinant human type IIA-
GST (IIA) only recognizes the exon 2 domain of type II procollagen
(Oganesian et al., 1997). Rabbit antisera IIC reacts with bovine COOH-
propeptide of type II collagen (provided by Dr. A. Robin Poole) and rat
antisera against bovine type II collagen, IIF (provided by Dr. M. Cremer),
recognizes the triple-helical domain of type II collagen. Preimmune sera
from the rabbit producing anti–type IIA procollagen antibodies and non-
immune rat serum (Jackson ImmunoResearch Laboratories, Inc.) were
used as controls. Anti–human integrin
 
 b
 
1 mAb (GIBCO BRL) was used
to demarcate the periphery of chondrocytes.
TGF-
 
b
 
1 antibodies were obtained from Santa Cruz Biotechnology.
They are specific for active TGF-
 
b
 
1. IGF-1 antiserum was from Austral
Biologicals. The BMP-2/4 mAb (AbH3b2/17) was kindly provided by Dr.
Elizabeth Morris (Genetics Institute, Cambridge, MA). This reagent,
AbH3b2/17, was made by standard mAb procedures using full length re-
combinant human BMP-2 as the immunogen. It reacts with both BMP-2
and BMP-4. Details of antibody specificity have been described in
Yoshikawa et al. (1994) and Bostrom et al. (1995).
 
Immunofluorescence Staining 
 
Frozen sections (8–10 
 
m
 
m) mounted on polylysine coated slides (Fisher
Scientific Co.) were fixed in 4% paraformaldehyde for 10 min at room
temperature, and incubated with hyaluronidase (1 mg/ml) for 30 min at
37
 
8
 
C. Sections were blocked in PBS containing 10% (vol/vol) normal don-
key serum (blocking buffer, Jackson ImmunoResearch Laboratories, Inc.)
for 1 h at 37
 
8
 
C. All primary antibodies were diluted in PBS containing
normal donkey serum (1% vol/vol). Antiserum IIA was used at a dilution
of 1:400, IIC was 1:100, IIF was 1:50, and integrin 
 
b
 
1 was 1:50. For double
immunostaining, primary antibodies (IIA and IIF, IIC and IIF, or integrin
 
b
 
1 and IIF) were mixed well and incubated with sections overnight at 4
 
8
 
C.
After washing in PBS, sections were incubated sequentially with appropri-
ate secondary antibodies [cyanine 3 conjugated donkey anti–rabbit IgG
F(ab
 
9
 
) fragment with a dilution of 1:200, FITC conjugated donkey anti–rat
IgG F(ab
 
9
 
) fragment with a dilution of 1:100, or cyanine 3 conjugated donkey
anti–mouse IgG F(ab
 
9
 
) fragment with a dilution of 1:200, Jackson Immuno-
Research Laboratories, Inc.] for 30 min at room temperature. Hoechst
dye 33258 (1 
 
m
 
g/ml, Calbiochem-Novabiochem Corp.) was used for fluo-
rescent nuclear stain for 10 min at room temperature. After washing, sec-
tions were mounted in fluorescent mounting medium (Vector Laborato-
ries, Inc.) and viewed on a Nikon Optiphot using DM445 (for Hoechst
dye), DM510 (for FITC), and DM580 (for cyanine 3) filter cubes. Normal
rabbit and rat serum were used as control instead of primary antibodies.
 
Microscopy 
 
Images were collected on a BioRad MRC600 scanning laser confocal mi-
croscope mounted on a Nikon Optiphot. Data were collected using either
a Nikon 20
 
3
 
/0.50 or a 40
 
3
 
/0.70 NA dry objective. The BioRad A1-A2
cubes were used with an Argon laser producing excitation at 514 nm and
collecting emission at 520–560 nm (green) and 
 
.
 
600 nm (red). Optical
sections were 
 
z
 
2 
 
m
 
m with the 20
 
3
 
 objective and 1 
 
m
 
m with the 40
 
3
 
 objec-
tive. Full frame (768 
 
3
 
 512) 8-bit images were collected for analysis and
overlaid in 24-bit RGB using Adobe Photoshop.
High resolution images were collected on a Deltavision SA3.1 wide-
field deconvolution optical sectioning device (Applied Precision, Inc.)
mounted on an Olympus IMT-2 microscope. Data were collected using ei-
ther a Nikon 60
 
3
 
/1.4 or 100
 
3
 
/1.4 NA objective using oil with an i.r.
 
 5
 
1.515. Hoechst dye 33258 (blue) was excited at 360/20 nm and emission
collected at 457/25 nm. Fluorescein (green) was excited at 490/10 nm and
emission collected at 528/19 nm. Cyanine 3 (red) was excited at 555/14 nm
and emission collected at 617/36 nm. Optical sections were collected at 200
nm per step and deconvolved with a measured optical transform function
per Sedat and Agard (Hiraoka et al., 1990, 1991). Under these conditions
we normally obtained 90 nm lateral and 400 nm axial resolution. Images
were collected at 512
 
 3
 
 512 pixels at 12-bits/pixel. Final pixel depth is 16-
bit. Images were exported as 24-bit TIFF images.
 
Immunoelectron Microscopy 
 
The immunolocalization techniques used have been described previously
(Reinhart et al., 1996). In brief, for en bloc localization of type IIA in fetal
 
cartilage, samples were first exposed to chondroitinase ABC (Sigma
Chemical Co.), 290 U/ml PBS for 2 h at 37
 
8
 
C, followed after rinsing by im-
mersion overnight at 4
 
8
 
C in primary antibody (pAb IIA) diluted 1:5 in
PBS. After a substantial wash in PBS, the samples were immersed in goat
anti–rabbit 5-nm secondary gold conjugate (Amersham Corp.) diluted 1:3
in BSA, pH 7.8, overnight at 4
 
8
 
C. The samples were washed, fixed in alde-
hydes containing in 0.1% (wt/vol) tannic acid for 60 min followed by 1%
OsO
 
4
 
 for 120 min, then dehydrated and embedded in Spurr’s epoxy.
To further clarify the localization of type IIA procollagen NH
 
2
 
-propep-
tide within the fibrils, cartilage containing perichondrium from the same
fetus was sheared in 0.2 M ammonium bicarbonate, pH 7.6, using an Omni
International 2000 homogenizer. The homogenate was washed three times
with resuspension in PBS and centrifugation at 600 
 
g
 
 for 5 min. The result-
ing homogenate was either directly deposited onto carbon coated grids
and stained with 3% phosphotungsic acid, pH 7.0, labeled only with pri-
mary antibody (1:5 in PBS) before staining, or labeled with primary anti-
body followed by secondary antibody 5-nm gold conjugate (1:3 in BSA)
before staining.
 
Cell Cultures 
 
RCJ 3.1 C5.18 cells were maintained in 
 
a
 
-MEM supplemented with 10%
heat-inactivated FCS (Grigoriadis et al., 1989). The cells were labeled af-
ter the last medium change for 24 h in serum-free 
 
a
 
-MEM (5 ml/dish) sup-
plemented with 50 
 
m
 
g/ml ascorbate and 50 
 
m
 
g/ml 
 
b
 
-aminoproprionitrile
fumarate and containing 25 
 
m
 
Ci/ml of [
 
3
 
H]proline (
 
.
 
20 Ci/mmol, Amer-
sham Corp.) and 50 
 
m
 
Ci/ml of [
 
35
 
S]cysteine (1071 Ci/mmol, Amersham
Corp.). After 24 h of culture, the medium was adjusted to 5 mM EDTA
and 1 mM 
 
N
 
-ethylmaleimide. Proteins were precipitated by the addition
of 300 mg/ml of ammonium sulfate which was stirred overnight at 4
 
8
 
C.
The precipitate was collected by centrifugation at 15,000 rpm at 4
 
8
 
C for 30
min in an SS34 rotor (Sorvall Instrument). The precipitate was suspended
in 1 ml PBS and then dialyzed for 48 h against the same buffer.
The total RNA was extracted from RCJ 3.1 C5.18 cells by TRIZOL
Reagent (GIBCO BRL) following the manufacturer’s instructions. RT-
PCR was used to identify type IIA and IIB mRNA. Two primers, 5
 
9
 
-
TCGGGGCTCCCCAGTCGCTGGTG-3
 
9
 
 (exon 1) and 5
 
9
 
-GATGGA-
GAACCTGGTACCCCTGGA-3
 
9
 
 (exon 7), were used to amplify type
IIA and IIB cDNA fragments which are 457 and 253 bp, respectively.
PCR products were electrophoresed on 1.5% agarose gel and stained with
ethidium bromide.
To identify type II procollagens, the proteins collected from culture
medium were separated on 5% SDS-polyacrylamide gel and then ana-
lyzed by Western blotting. Three antibodies, rabbit anti-IIA 
 
1 
 
GST (IIA)
at 1:1,000 dilution, rat anti-IIF at 1:500, and rabbit anti-IIC at 1:1,000,
were used. Anti–rabbit and –rat IgG conjugated with HRP (Jackson Im-
munoResearch Laboratories, Inc.) were applied and detected by SuperSi-
gal
 
®
 
 Chemiluminescent Substrate (Pierce Chemical Co.). Pepsin solubi-
lized chick type II collagen (Sigma Chemical Co.) was used to indicate the
migration of the type II collagen 
 
a 
 
chain.
 
Expression of Recombinant Human Type IIB
Collagen NH
 
2
 
-propeptide 
 
RT-PCR was carried out to amplify a 315-bp fragment encoding the entire
common domain of the type II collagen NH
 
2
 
-propeptide from exon 3 (be-
ginning of minor helix) through exon 8 (beginning of the major helix)
from 54-d human fetal embryonic tissue total RNA. The forward 35-mer
primer was 5
 
9
 
-AATGGATCCCAACCAGGACCAAAGGGACAGA-
AAGG-3
 
9
 
. The reverse 29-mer primer was 5
 
9
 
-ATATGCGGCCGCCAT-
TGGTCCTTGCATTACTCCCAACTGGGC-3
 
9
 
. PCR products were di-
gested with BamHI and NotI, and cloned into a pGEX-4T-2 vector
(Pharmacia Biotech, Inc.). cDNA sequencing was used to confirm the cor-
rect reading frame.
The expression and purification of the recombinant human type II col-
lagen NH
 
2
 
-propeptide (rhIIN-GST, exons 3–8) was carried out by Bulk
and RediPack GST purification modules (Pharmacia Biotech, Inc.) fol-
lowing the manufacturer’s instructions. The fusion protein (rhIIN-GST)
was analyzed by rabbit anti–IIA 
 
1 
 
GST antibody or goat anti-GST anti-
body (Pharmacia Biotech, Inc.) on Western blotting.
 
Immunoprecipitation 
 
60 nM recombinant human type IIA procollagen NH
 
2
 
-propeptide (rhIIA-
GST, exon 2-GST fusion protein; Oganesian et al., 1997), 60 nM human 
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IGF-1 (R&D Systems), or 15 nM human BMP-2 (Genetics Institute) was
incubated for 1 h at room temperature in 1 ml of PBS containing 1 mM
CaCl
 
2
 
, 3 mM MgCl
 
2
 
, and 1 mg/ml BSA. 10 
 
m
 
l rabbit antisera against NH
 
2
 
-
propeptide or preimmune serum was added to the samples and incubated
for 2 h at 4
 
8
 
C. 20 
 
m
 
l of protein A–Sepharose beads (Pharmacia Biotech)
were added and incubated for 3 h. Beads were pelleted for 1 min and pre-
cipitated immune complexes were washed five times with 1 ml PBS, pH
7.2, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and once with 1 ml
of 10 mM Tris-HCl, pH 6.8. The samples were resuspended in 40 ml
Laemmli sample buffer (without DTT), boiled for 5 min, electrophoresed
through SDS polyacrylamide gels under nonreducing conditions, and elec-
troblotted onto PVDF membranes. The membranes were blocked with
10 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween 20 containing 3% BSA,
and incubated in the same buffer for 1 h at room temperature with pri-
mary antibody, anti–human BMP monoclonal or anti–human IGF-1 mono-
clonal (Austral Biologicals), both at a dilution of 1:500. Anti–mouse sec-
ondary antibodies were used and detected by Western blue stabilized
substrate for alkaline phosphatase (Promega Corp.).
For comparison of binding to IIA and IIB procollagens, recombinant
proteins for type IIA NH2-propeptide (rhIIA-GST) or II NH2-propeptide
(rhIIN-GST, exons 3-8 of the NH2-propeptide) were mixed with BMP-2 as
above and immunoprecipitated with BMP specific antiserum. Immuno-
precipitates were separated by electrophoresis on a 15% SDS polyacryl-
amide gel, transferred to PVDF membranes, and reacted with antiserum
to type IIA-GST.
To test whether BMP-2 binds to natural type IIA procollagen, the 3H-
and 35S-labeled proteins collected from C5.18 cell medium were immuno-
precipitated with BMP-2 antibody. In brief, 100 ml of labeled proteins di-
luted in NET-buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% NP-40,
1 mM EDTA, pH 8.0, and 0.25% gelatin) to 1 ml was mixed with 10 ml of
mouse serum–agarose (Sigma Chemical Co.) for 1 h at 08C. Mouse serum–
agarose was discharged after centrifugation. 200 ng of BMP-2 was added
to the supernatant and incubated for 1 h at 48C, then 5 ml of BMP-2 anti-
body was applied and incubated an additional 1 h at 48C. After incubation,
20 ml of protein A–Sepharose beads (Pharmacia Biotech, Inc.) was added
and incubated for 1 h at 48C. Beads were pelleted for 1 min and the pre-
cipitated immunocomplexes were washed three times with 1 ml NET-
buffer. The samples were resuspended in 30 ml Laemmli sample buffer
and boiled 5 min. Normal mouse serum was used as negative control, in-
stead of BMP-2 antibody. The type IIA procollagen and type II collagens
were immunoprecipitated by rabbit antiserum to type IIA-GST and rat
antiserum against the fibrillar domain of type II collagen. Labeled pro-
teins were visualized by autoradiography after separation on 5% SDS
polyacrylamide gel using Amplify (Nycomed Amersham Inc.).
Solid Phase Binding Assay 
96-well flat bottomed plates (Costar, High Binding, E.I.A./R.I.A. #3590)
were coated overnight at 48C with 5 or 10 ng/well TGF-b1, BMP-2, bFGF,
IGF-1, and GST in 0.1 M Tris-HCl, 50 mM NaCl, pH 7.4 (Tris-NaCl), re-
spectively. Plates were washed three times with PBS, pH 7.2, containing
0.1% (vol/vol) Tween 20 (PBS/Tween). To block nonspecific binding,
plates were incubated for 1 h at 208C with PBS/Tween containing 3% (wt/
vol) BSA and washed four times in PBS/Tween. Dilutions of rhIIA-GST
fusion protein and GST (Oganesian et al., 1997), from 1 to 5,000 ng/well,
in Tris-NaCl were added to the coated wells and incubated at 378C for 2 h.
Plates were washed five times with PBS/Tween. Plates were incubated for
4 h with PBS/Tween/BSA buffer, then incubated for 2 h at 208C with a
1:1,000 dilution of anti–IIA-GST antibodies in PBS/Tween. Plates were
washed five times with PBS/Tween and incubated for 2 h at 208C with a
1:5,000 dilution of goat anti–rabbit IgG-alkaline phosphatase conjugate in
PBS/Tween and washed five times with PBS/Tween. Plates were incu-
bated for 30–60 min with 3 mM p-nitro-phenylphosphate substrate in 0.05 M
Na2CO3 and 0.05 mM MgCl2 buffer, and absorbance was measured at 405
nm using a Hewlett Packard ELISA microplate reader. In addition, the
substrates and ligands were reversed. rhIIA-GST fusion protein or IIA
protein (only exon 2) alone was plated at 10 ng/well. BMP-2 and mAb
against rhBMP-2 were incubated sequentially as above. Then, secondary
antibody and color reactive substrate were used to detect the binding.
Each data point was in duplicate from three independent experiments.
Results
Type IIA NH2-propeptide Is Present in
Prechondrogenic Mesenchyme 
To determine whether type IIA procollagen is involved in
early stages of chondrogenesis, we investigated the specific
localization of the NH2-propeptide before and during
chondrogenesis. In the developing limb, distal skeletal
structures differentiate later than proximal structures (Ham,
1974). Therefore, 50-d human embryonic limb tissue was
used because many stages of chondrogenesis can be ob-
served. Antibodies specific for different domains of the
collagen molecule were used to localize the IIA NH2-
propeptide, COOH-propeptide, and triple-helical (fibril-
lar) domains of type II procollagen. RNA probes were
used to confirm the distribution of mRNA. The approxi-
mate locations of epitopes and mRNA probes are shown
in Fig. 1.
Double immunofluorescence was performed on tissue
sections using the triple-helical antibody together with ei-
ther the NH2- or COOH-propeptide–specific primary anti-
bodies and fluorescent secondary antibodies. Fluorescence
was visualized by confocal laser-scanning microscopy (Fig.
2). In the condensing mesenchyme of the emerging digital
rays, signal for type IIA NH2-propeptide can be observed
Figure 1. Diagram of alternative
splicing of type IIA procollagen
gene. (A) Probes were designed
to detect the two splice forms of
type II procollagen mRNA. A
riboprobe (black bar) is specific
for type IIA mRNA (1exon 2)
and the oligonucleotide probe
(gray bar) spans the splice junc-
tion and is therefore specific for
type IIB procollagen mRNA.
(B) Three antibodies were used
to localize the type II procol-
lagen domains. Triangles indi-
cate potential epitopes for a rab-
bit antiserum against human
recombinant exon 2, squares indicate epitopes for a rat antiserum against bovine type II collagen fibrillar domains, and circles indicate
rabbit antiserum against bovine type II collagen COOH-propeptide. The specific number of epitopes for each antiserum is unknown.Zhu et al. Type IIA Procollagen and BMP 1073
colocalized with the triple-helical domain (Fig. 2, A–C).
At this time, the cells are closely packed condensations
and there is no evidence of chondrocyte-characteristic
morphology. In serial sections, mRNA levels are below
the level of detection with routine in situ hybridization.
However, the more sensitive immunolocalization identi-
fies these cells as the site of future cartilage differentiation.
More proximal in the developing radius, different stages of
chondrogenesis are present. D–F in Fig. 2 show the distri-
bution of type IIA and IIB procollagen mRNA splice
forms. Type IIA collagen mRNA is synthesized by chon-
droprogenitor (CP) cells and type IIB collagen by chon-
droblasts and chondrocytes (C). In chondroprogenitor tis-
sue, where only type IIA procollagen mRNA is detected,
both NH2-propeptide (red, Fig. 2 G) and triple-helical do-
mains (green, Fig. 2 H) are colocalized (reddish/yellow,
Fig. 2 I). There is a gradient of distribution of type IIA
NH2-propeptide with the greatest immunoreactivity in
the chondroprogenitor zone. The gradient distribution of
fibrillar domain in H exceeds the range of sensitivity of the
detector. Consequently, the green fluorescence in the CP
region is underrepresented to reduce blurring due to the
high signal in the C region. In the chondroblasts and chon-
drocytes, where type IIB mRNA is detected, the NH2-
propeptide can still be visualized in the ECM (C in Fig. 2,
G and I). In contrast to the NH2-propeptide, double im-
munofluorescence using antibodies to the COOH-propep-
tide and triple-helical domains reveals a different pattern
of fluorescence (Fig. 2, J and K). The COOH-propeptide
is not colocalized with the triple-helical domains in the
ECM, but appears to be localized inside the cells (red dots
in Fig. 2 J and yellow dots in Fig. 2 L).
Type IIA NH2-propeptide Is Deposited in the ECM 
To define more precisely the localization the type II pro-
collagen domains during chondrogenesis, tissue sections
were visualized using Delta Vision™ microscopy. The
Delta Vision™ system utilizes broad field optics coupled
with computerized deconvolution of the optical image us-
ing Fourier transformation. A Z-stack of optical sections
through 3.2 mm can be viewed with a resolution of z90
nm. Selected fields representing stages of chondrogenesis
shown in Fig. 2 are presented in Fig. 3. In addition to the
immunolabeling of collagen domains shown above in con-
focal micrographs, the fluorescent dye Hoescht 35258 can
be used to identify nuclei. Immunoreactivity of the NH2-
propeptide (red) and fibrillar domains (green) merged im-
ages are shown. Independent visualization of single fluo-
rescence confirmed localization of both Cy3 (red) and
Figure 2. Double labeled immu-
nofluorescence of human fetal
limb during chondrogenesis
viewed by confocal laser scan-
ning microscopy. Both type IIA
procollagen NH2-propeptide
(A, red) and triple-helical do-
mains (B, green) are localized in
the ECM of condensing cells of
the emerging digital rays (C).
D–F show differential expres-
sion of type IIA and IIB procol-
lagen mRNA in a 50-d human
fetal limb. (D) Bright-field pho-
tograph of the hand showing the
condensation of chondropro-
genitor cells (CP) and chondro-
cytes (C). (E) Localization of
type IIA procollagen mRNA by
in situ hybridization to chondro-
progenitor cells. (F) Expression
of type IIB mRNA in a serial
section. E and F are photo-
graphed with dark-field illumi-
nation. Bar, 200 mm. G–I show
type IIA NH2-propeptide (G,
red) and triple-helical domains
(H, green) in chondroprogenitor
cells (CP), the ECM of cartilage,
and the perichondrium in the
growth cartilage of 50-d human
fetal limb. The COOH-propep-
tide is immunolocalized within
cells and not in the ECM
throughout stages of chondro-
genesis (J and L). Bar in A–C
and G–L, 72 mm.The Journal of Cell Biology, Volume 144, 1999 1074
Figure 3. Double immunohistochemistry
of growth cartilage in a 50-d gestation hu-
man fetal limb. A–D were reacted with
antisera to type II collagen fibrillar do-
main (green) and type IIA procollagen
NH2-propeptide (red). In all panels, yel-
low or reddish-yellow color indicates colo-
calization. E and H were reacted with an-
tibody to type II collagen fibrillar domain
(green) and type II collagen COOH-
propeptide (red). G was a negative con-
trol, and H showed the antibody to inte-
grin b1 (red) and type II collagen fibrillar
domain (green). Labels indicate nucleus
(N), extracellular matrix (M), and secre-
tory granules (SG). Arrow in B and C in-
dicate ECM. Bars in A–D, 9.0 mm and in
E–H, 5.4 mm.Zhu et al. Type IIA Procollagen and BMP 1075
FITC (green) in regions that appear orange or orange-red.
As shown above, chondroprogenitor cells (Fig. 3 A) syn-
thesize type IIA procollagen mRNA while more mature
chondrocytes (Fig. 3, B–D) synthesize type IIB procol-
lagen. In the chondroprogenitor tissue, the cells are tightly
packed with large nuclei, little cytoplasm, and very little
ECM is observed. However, the small amount of staining
around the cells can clearly be seen in this merged image
to be reddish yellow (Fig. 3 A) indicating colocalization of
NH2-propeptide and the triple-helical domains. In chon-
droblasts (Fig. 3 B), an accumulation of type IIA NH2-
propeptide and fibrillar collagen can be observed. Less
mature cells are in the upper left half of the photograph
while the more mature chondrocytes are in the lower right
half of the photograph. In the zone of mature chondro-
cytes (Fig. 3 C), the cells are even larger and contain dis-
tinct secretory granules lying close to the nucleus. More
cellular detail in these rounded cells can now be resolved.
In the ECM, reddish orange-staining areas of propeptide
are localized in the interterritorial matrix where it has
been displaced by newly synthesized type IIB procollagen
(green). In previous studies and shown above, in situ hy-
bridization to mRNA demonstrated that these chondro-
cytes transcribe only type IIB procollagen mRNA and no
longer synthesize the type IIA NH2-propeptide. The newly
synthesized type IIB procollagen can be seen in the secre-
tory granules surrounding the nucleus and deposited im-
mediately around the cell. Fig. 3 D shows the hypertrophic
zone where streaks of type IIA procollagen remain in a
matrix that contains primarily type IIB collagen. To fur-
ther confirm the extracellular localization of the NH2-
propeptide, serial sections were stained with antibodies to
type II procollagen COOH-propeptide, type II triple-heli-
cal domain, and integrin b1 (Fig. 3, E–H). In Fig. 3 (E and
F), the double immunohistochemistry with anti–COOH-
propeptide and anti-helical domain antibodies is shown.
Note that only the triple-helical domain (green) is depos-
ited into the ECM of chondroprogenitor cells while the
COOH-propeptide (red) is colocalized with the triple-
helical domain in the secretory granules (yellow in Fig. 3,
E and F) or alone (red). The intercellular structures stain-
ing with the COOH-propeptide antiserum (only red in Fig.
3, E and F) is currently under investigation. Most of these
structures do not react with the Golgi apparatus or endo-
plasmic reticulum characteristic antibodies, such as anti-
Golgi 58K protein and anti-Hsp47, respectively (data not
shown). Preimmune serum used as the primary antiserum
is shown as a negative control (Fig. 3 G) and the cell pe-
riphery was confirmed by localization of integrin b1 (Fig. 3
H). The yellow signal indicates that integrin b1 is colocal-
ized with type II collagen triple-helical domains (Fig. 3 H).
Electron Microscopic Immunolocalization of Type IIA 
Procollagen Fibrils
To determine the molecular organization of the NH2-
propeptide, localization of type IIA procollagen in em-
bryonic chondrogenic tissue was performed and visualized
using electron microscopy. Antiserum to the NH2-propep-
tide was used to localize the procollagen in tissue (Fig.
4 A). The results demonstrate localization of antibody-
bound gold particles on the surface of collagen fibrils
present in perichondrial tissue. The fibrils shown here also
react with the type II collagen helical domain antibody. To
further clarify the position of the NH2-propeptide within
the fibrils, individual fibrils were released from tissue ma-
trix by shearing in ammonium bicarbonate buffer using a
tissue homogenizer (Fig. 4 B), incubated only with type
IIA specific antibody (Fig. 4 C), then further incubated
with 5-nm gold secondary antibody conjugate (Fig. 4 D).
Before antibody treatment, the fibrils have an irregular
surface (Fig. 4 B) and the periodic banding pattern of type
II collagen characterized by Eikenberry et al. (1984). Af-
ter incubation with type IIA antibody, protrusions from
the fibril surface can be seen (arrow in Fig. 4 C). The iden-
tity of the protrusions as primary antibody is confirmed by
secondary antibody–gold conjugate (black dots in Fig. 4
D). A determination of periodicity following gold conju-
gate is complicated by the additional length of the com-
plex (primary antibody–secondary antibody–gold parti-
cles) and by some secondary antibodies carrying more
than one gold particulate. Therefore, the estimate of anti-
gen spacing was made from the primary antiserum photo-
micrographs. Taken together, these results indicate that
the NH2-propeptide is present at the surface of the type II
collagen fibril and found at locations corresponding to the
periodic repeat of the collagen molecule.
Figure 4. Fetal tissue undergoing chondrogenesis immunola-
beled en bloc with antibody specific to the NH2-propeptide of
type IIA procollagen (A). Collagen fibrils sheared from fetal car-
tilage and observed following staining in PTA demonstrate a 70-nm
periodicity (arrows, B). Following incubation in antibody, the
fibrils are seen to label with a 70-nm periodicity (arrows, C). The
identity of the label as antibody is confirmed by addition of sec-
ondary antibody–gold conjugate (D). Bars: (A) 100 nm; (B–D)
100 nm.The Journal of Cell Biology, Volume 144, 1999 1076
Type IIA Procollagen NH2-propeptide Binds to TGF-b1 
and BMP-2 
The presence of type IIA NH2-propeptide in ECM of
chondroprogenitor cells suggests that it has a function be-
fore differentiation of the chondrocyte and could play a
role in the induction of chondrogenesis. To assay for bind-
ing, immunoprecipitation of BMP-2 and IGF-1 with IIA
NH2-propeptide antibody was performed. rhIIA-GST pro-
tein isolated from the recombinant GST fusion protein
was used. rhIIA (60 nM), human recombinant BMP-2 (15
nM), or IGF-1 (60 nM) was incubated for 1 h at room tem-
perature in 1 ml of PBS binding buffer, immunoprecipi-
tated with anti-IIA NH2-propeptide antibody, and the
amount of BMP-2 or IGF-1 bound to rhIIA protein was
detected on Western blots with monoclonal anti–BMP-2
or IGF-1 antibody. As shown in Fig. 5 A (lane 1) BMP-2
can be immunoprecipitated by IIA NH2-propeptide anti-
serum. Control reactions show no immunoprecipitation
with BMP-2 alone (Fig. 5 A, lane 2) and no immunopre-
cipitation of the BMP-2–rhIIA protein complex with pre-
immune serum (Fig. 5 A, lane 3). No immunoreactivity for
IGF-1 was detected when a mixture of IGF-1 and exon 2
protein was immunoprecipitated with NH2-propeptide an-
tiserum (Fig. 5 A, lane 5).
To determine whether BMP-2 binding was specific for
the type IIA splice form of type II collagen, binding of
BMP-2 to recombinant type IIA (rhIIA, exon 2) was com-
pared with binding to recombinant type IIB NH2-propep-
tide (rhIIN, exons 3–8; Fig. 5 B). Immunoprecipitation was
performed by mixing 4.0 mg human recombinant type IIA
fusion protein (rhIIA-GST), and 1.0 mg BMP-2 or human
recombinant type IIB NH2-propeptide (rhIIN-GST), and
BMP-2 and precipitating with antibody to BMP-2. West-
ern blot analysis was performed and recombinant type IIA
fusion protein identified with specific antiserum. Type IIA
(rhIIA-GST) was immunoprecipitated with antiserum to
BMP (Fig. 5 B, lane 1), but recombinant type IIB NH2-
propeptide (rhIIN-GST; Fig. 5 B, lane 2) nor GST (Fig. 5
B, lane 3) could be immunoprecipitated. Fig. 5 B, lanes
4–6, shows that antisera against rhIIA-GST can react with
rhIIA (exon 2), rhIIN-GST (exons 3–8), and GST when
they are run on the gel.
BMP-2 Binds Only to the Type IIA Procollagen Isoform 
Media from C5.18 cultured chondroblasts was used to
demonstrate binding of natural type IIA procollagen to
BMP-2. Fig. 6 A shows that cells express mRNA for both
type IIA and IIB procollagens. Protein products were sep-
arated on a 5% SDS-polyacrylamide gel and transferred to
PVDF membrane for Western blot analysis of type II col-
lagens (Fig. 6 B). Lanes 1 and 3 show immunoreactivity
with the type IIA NH2-propeptide antiserum and type II
COOH-propeptide antiserum, identifying this band as
pNC type IIA procollagen, shown previously for human
cells (Oganesian et al., 1997). Antiserum to the fibrillar
domain of type II collagen indicates the presence of multi-
ple forms of type II collagen in the medium (Fig. 6 B, lane
2). These forms include type IIA pNC procollagen, type
IIB pNC procollagen, type II pC procollagen, and mature
a chains (Sandell et al., 1991). Pepsin solubilized type II
collagen a chain is shown in Fig. 6 B, lane 4. Specific anti-
sera were used to precipitate procollagens from the me-
dium, type IIA procollagen (Fig. 6 C, lane 1), and all type
II collagens (Fig. 6 C, lane 2). When recombinant BMP-2
was added to the medium and proteins immunoprecipi-
tated with BMP-2 antibody, type IIA procollagen alone
was observed (Fig. 6 C, lane 3).
To estimate the strength of interaction between NH2-
propeptide and BMP-2, the binding of various growth fac-
tors to alternatively spliced type IIA procollagen NH2-
propeptide domain (rhIIA) expressed as a GST-fusion
protein was tested. The growth factors bFGF, IGF-1,
Figure 5. Immunoprecipitation of type IIA NH2-propeptide–
BMP-2 complex. (A) BMP-2 bound to rhIIA-GST protein can be
immunoprecipitated by type IIA NH2-propeptide antisera (lane
1). Control reactions show no immunoprecipitation with BMP-2
alone (lane 2), and immunoprecipitation of BMP-2–rhIIA-GST
complex with preimmune serum (lane 3). A mixture of IGF-1
and exon 2 protein was not immunoprecipitated with type IIA
NH2-propeptide antiserum (lane 5). Lanes 4 and 6 show BMP-2
(33 kD) and IGF-1 (7 kD) alone, respectively. (B) Recombinant
type IIA protein (rhIIA) bound to BMP-2 can be immunoprecip-
itated by BMP-2 antibody and reacted with anti-IIA 1 GST anti-
serum (lane 1), neither type II collagen NH2-propeptide (rhIIN,
exons 3–8, lane 2) nor GST (lane 3) can be immunoprecipitated.
Lanes 4–6 show recombinant type IIA NH2-propeptide (rhIIA),
type II NH2-propeptide (rhIIN) and GST were reacted with anti-
IIA 1 GST antiserum.Zhu et al. Type IIA Procollagen and BMP 1077
BMP-2, and TGF-b1, all known to be involved in chondro-
genesis, were tested in a solid phase binding assay. Fig. 7 A
shows the results of binding of rhIIA-GST to immobile
BMP-2, bFGF, and IGF-1. rhIIA-GST was added in in-
creasing concentrations and the amount bound was mea-
sured with antiserum to NH2-propeptide. No binding of
rhIIA-GST was observed with bFGF and IGF-1 up to 10
mg/well (Fig. 7 A). Similar results were observed with
TGF-b1 (Fig. 7 B). Similar results were also obtained
when substrates and ligands were reversed, i.e., rhIIA-
GST was coated on plates and exposed to BMP-2. Anti-
body to BMP-2 was used to detect binding (data not
shown). Scatchard plot analysis of the interaction indi-
cated a KD of 7.65 nM for TGF-b1 and 5.23 nM for BMP-2.
Discussion
The mechanism of induction and differentiation of the
skeleton represents a basic developmental question and
thus has attracted a great deal of attention. Substantial
progress has been made in clarifying the roles of pattern-
ing genes such as pax, hox, hedgehogs, FGFs, genes that
induce musculoskeletal cell phenotypes such as the Myo D
family of transcription factors, and the extracellular signal-
ing factors, BMPs. The findings presented here indicate
that type IIA procollagen could potentially play a role in
induction and differentiation of the skeleton. Type IIA
procollagen is synthesized by chondroprogenitor cells and
deposited into the ECM. It retains the NH2-propeptide,
but the COOH-propeptide is removed. The NH2-propep-
tide of type IIA procollagen binds to BMP-2 and TGF-b1,
factors present in the tissue and known to induce chondro-
genesis in vivo (Wang et al., 1990) and in vitro, respec-
Figure 6. The natural type IIA procollagen binds to BMP-2. (A)
Type IIA and IIB procollagen mRNA (lane 2) were amplified by
RT-PCR from C5.18 cell total RNA. Lane 1 is a pGEM DNA
marker. (B) Western blotting of type II collagens. Lanes 1 and 3
show immunoreactivity with type IIA NH2-propeptide antiserum
and COOH-propeptide antiserum indicating this band is pNC
type IIA procollagen (PNCIIA, lane 2). Antiserum to the fibril-
lar domain of type II collagen indicates the presence of multiple
forms of type II collagen in the culture medium, including type
IIA pNC procollagen, type IIB pNC procollagen, type II pC pro-
collagen, and mature a chains (a1[II]). Pepsin solubilized a1(II)
is shown in lane 4. (C) Type IIA procollagen (lane 1) and all type
II collagens (lane 2) were immunoprecipitated by specific anti-
sera from the labeled proteins collected from C5.18 culture me-
dium. When recombinant BMP-2 was added to labeled proteins
and immunoprecipitated with BMP-2 antibody, only type IIA
procollagen was presented (lane 3), but not with normal mouse
serum (lane 4).
Figure 7. BMP-2 (A) and TGF-b (B) bind specifically to rhIIA-
GST (type IIA NH2-propeptide) fusion proteins. Solid phase
binding assays were performed in 96-well plates coated with 5 or
10 ng/well BMP-2 (A) or TGF-b1 (B). GST alone or rhIIA-GST
fusion proteins (1–5,000 ng/well) were added. The amount of
binding was detected by IIA NH2-propeptide antiserum and sec-
ondary antibody conjugated to alkaline phosphatase. Free rhIIA
fusion protein was determined by subtracting the bound rhIIA-
fusion protein from total rhIIA-GST fusion protein. Scatchard
analysis (inset) of the data (using Cricket Graph) resulted in a KD
of 5.23 nM for BMP-2 and 7.65 nM for TGF-b1.The Journal of Cell Biology, Volume 144, 1999 1078
tively (Denker et al., 1995). These results show for the first
time that type IIA pN-procollagen is deposited into the
ECM and suggest a novel function for the collagen NH2-
propeptide. Type IIA procollagen is the predominant
form of type II collagen in chondroprogenitor tissue and
remains in the tissue after cells switch synthesis to type IIB
collagen. Over time however, the predominant collagen
becomes type IIB collagen, and the type IIA procollagen
is removed. We do not know what enzymes are involved in
type IIA procollagen turnover or whether the NH2-pro-
peptide alone is cleaved from the collagen fibril, although
the NH2-propeptide can be cleaved by stromelysin, which
cleaves between the N-protease cleavage site and the be-
ginning of the major triple helix (Wu et al., 1991), an en-
zyme known to be increased in hypertrophic cartilage
(Zhu, Y., and L.J. Sandell, unpublished observations) and
the collagen N-protease which cleaves 8 amino acids down-
stream of the minor triple helix of the propeptide (Prockop
et al., 1998). Piccolo et al. (1997) have shown recently that
the chordin–BMP-4 complex is proteolytically processed
in chordin by the matrix metalloprotease xolloid, thereby
releasing active BMP-4. Cleavage of chordin alone inhibits
its ability to bind BMP-4. A similar cleavage mechanism
by a related enzyme, tolloid, occurs in the sog–dpp com-
plex (Marques et al., 1997). For type IIA procollagen, an
analogous cleavage mechanism may exist, as both N-pro-
tease and stromelysin are members of the same class of as-
tacin proteases as tolloid and xolloid.
The data presented here suggest that BMPs may be lo-
calized to sites of chondrogenesis by direct interaction
with the NH2-propeptide of type IIA procollagen. Support
for this hypothesis is derived from a similar interaction of
chordin and sog, homologues of the NH2-propeptide, with
BMP-4 (Piccolo et al., 1996) and decapentaplegic (Sasai
et al., 1995). The interactions regulate presentation of the
morphogen to the cell. The homology between sog, chor-
din, and NH2-propeptide includes placement of 10 cys-
teines, conserved across types I, IIA, III, and a2 (V) col-
lagens and thrombospondin, and placement of amino acids
glycine, tyrosine, tryptophane, proline, glycine, and pro-
line at residues 38, 41, 47, 82, 84, and 92 of the type IIA
procollagen NH2-propeptide. Although we have not di-
rectly compared the binding of chordin or sog with type
IIA NH2-propeptide in the same assay system, we can
compare the estimated KD for the binding of BMP-4 to
chordin (3 3 10210 M) to the estimated KD for type II
NH2-propeptide binding to BMP-2 and TGF-b1 (5–7 3
1029 M). These values compare favorably with the binding
of BMPs to their receptors, 9 3 10210 M for Xenopus
BMP2/4 receptor (Graff et al., 1994), 2.5 3 10210 M for
thick veins dpp receptor (Penton et al., 1994), and a range
of 2 3 10210 to 3.5 3 1029 M for binding of BMPs to vari-
ous cell receptors (Iwasaki et al., 1995).
Another protein, noggin, can bind to BMP-4 and func-
tions similarly to chordin (Lamb et al., 1993) in dorsal–
ventral patterning and neural induction. Noggin is a
member of a new family of BMP-binding proteins which
includes gremlin in neural crest, the head-inducing factor
cerberus, and the tumor suppressor DAN (Hsu et al.,
1998). Although their binding affinities for BMP-4 are dif-
ferent (2 3 10211 M for noggin and 3 3 10210 M for chor-
din) both proteins are able to dorsalize mesoderm at 1 nM
in Xenopus embryos (Piccolo et al., 1996). Recently, nog-
gin has been shown to be involved in chondrogenesis. That
is, in noggin-deficient mice, among other central nervous
system and somite patterning defects, cartilage condensa-
tions initiate normally but develop hyperplasia, and devel-
opment of joints in the limb fails (Brunet et al., 1998). The
involvement of noggin in chondrogenesis is intriguing, and
the relationship between noggin and type IIA collagen
NH2-propeptide binding to BMP is unknown. However,
the expression pattern of noggin is quite different from
type IIA procollagen and more closely resembles the type
IIB procollagen splice form (primarily expressed in chon-
droblasts and chondrocytes; Ng et al., 1993; Sandell et al.,
1994). Consequently, its role in chondrogenesis is likely to
be different from type IIA procollagen. The primary se-
quence of noggin is not homologous to type IIA NH2-
propeptide.
Reddi and colleagues have investigated the binding of
ECM proteins to TGF-b and bone morphogenetic pro-
teins. They have shown that TGF-b, BMP-3 (Paralkar et al.,
1991), and BMP-7 (Vukicevic et al., 1994) bind avidly to
type IV collagen, and to a lesser extent, types I, VI, and IX
collagens and heparin. They do not bind to types II, III,
V, or X collagens, laminin, fibronectin, or proteoglycans
(Paralkar et al., 1990, 1991, 1992; Vukicevic et al., 1994).
Consistent with these results, we show the fibrillar domain
of type II collagen does not bind to BMP-2. In general,
only relative binding affinities were reported. However,
the  KD of BMP-7 and type IV collagen was estimated to be
5 3 10211 M (Vukicevic et al., 1994).
The localization of type IIA procollagen shown here is
consistent with a role for propeptide in regulating the dis-
tribution of BMPs. This localization could potentially ap-
ply in four primary, but distinct processes. The first is the
localization of type IIA procollagen at epithelial–mesen-
chymal boundaries. Wood et al. (1991) immunolocalized
type II collagen and we and others (Sandell et al., 1994;
Lui et al., 1995) have shown that these cells synthesize pre-
dominantly type IIA mRNA. Lui et al. (1995) showed type
II collagen mRNA is initially synthesized by neuroepithe-
lial cells, then by both epithelial and mesenchymal cells,
then only mesenchymal cells. The mesenchymal cells pro-
ceed to chondrogenesis because they express the receptors
necessary to respond to the inducing agent. Secondly, type
IIA procollagen is localized in prechondrogenic condensa-
tions before differentiation into chondrocytes, as shown
above. Thirdly, type IIA procollagen is transiently ex-
pressed in other areas where BMPs are involved in induc-
tion of differentiation and could be involved as nonchon-
drogenic processes. For example, type IIA procollagen
mRNA has been found in early kidney development, skin
before terminal differentiation of keratinocytes, develop-
ing aorta, lung buds, salivary gland, adrenal cortex, noto-
chord, somites, and apical ectodermal ridge in mice (Ng et
al., 1993; Sandell et al., 1994) and in humans (Sandell,
1994; Lui et al., 1995). Fourthly, type IIA is present in pe-
riosteum and perichondrium, predominant sites of ectopic
bone formation.
The mechanism of BMP induction of mesenchymal cells
after binding and localization by type IIA procollagen re-
mains to be clarified. It is possible that IIA-bound BMPs
could induce chondrogenesis. On the other hand, the NH2-Zhu et al. Type IIA Procollagen and BMP 1079
propeptide–BMP complex could be liberated by an amino
propeptidase or stromelysin, both known to be able to
cleave the propeptide (Wu et al., 1991) when these en-
zymes become available in the ECM. Lastly, the NH2-
propeptide–BMP complex could be disengaged, releasing
BMP to bind to the cellular receptor. Piccolo et al. (1996)
have hypothesized that chordin inactivates potential bind-
ing of BMP-2 to the cellular receptors, based on inhibition
of BMP-2 stimulation of osteogenesis in C3H10T1/2 cells.
While the binding mechanism between the chordin–
BMP-4 and NH2-propeptide–BMP-2 complexes may be
similar, the functional outcome may be quite distinct.
Chordin is synthesized and secreted as a soluble protein,
while type IIA procollagen is deposited into the ECM.
The NH2-propeptide can remain attached to the triple-
helical domain or be liberated by cleavage. Chordin is
thought to function by removing BMP-4 from the site of
potential inductive activity, in this case inducing ventral-
ization in Xenopus. A similar interaction occurs in the
dorsal ventral patterning in Drosophila. That is, the sog
(Francois et al., 1994), a homologue of type IIA NH2-
propeptide and chordin (Francois and Bier, 1995), func-
tions as an antagonist of decapentaplegic, a member of the
TGF-b superfamily (Padgett et al., 1993). The similar
functional outcome of interactions of chordin–BMP-4 and
sog–decapentaplegic establishes a conserved mechanism
for dorsal–ventral patterning that is shared by vertebrates
and arthropods (Piccolo et al., 1996).
The binding of type IIA NH2-propeptide to BMPs sug-
gests a novel function for this protein domain. We show
that type IIA procollagen is synthesized and deposited
into the ECM. This fibrillar domain of the collagen could
then provide a substrate for mesenchymal cells while the
NH2-propeptide localizes the protein capable of inducing
chondrogenesis. As the cells differentiate into chondro-
cytes, exon 2 encoding the NH2-propeptide is removed by
alternative splicing of the mRNA. Consequently, by con-
trolling the availability of NH2-propeptide, a mechanism is
built in to control the amount of morphogenetic agent the
cells are exposed to. Subsequently, type IIA procollagen is
synthesized in the perichondrium and periosteum (Ogane-
sian et al., 1997) where it can help establish a reservoir of
BMP. Pattern induction, whether in early body axis or ele-
ments of the skeletal system, is thus guided by the result of
a gradient of morphogen bound to a specific protein do-
main. We propose that the interactions of sog, chordin,
and type IIA procollagen NH2-propeptide with members
of the TGF-b superfamily represent a biological paradigm
whereby the presentation of morphogenetic proteins can
be regulated.
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